PCM
KRYS icon

Penserra Capital Management’s Krystal Biotech KRYS Stock Holding History

Penserra Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-510
Closed -$26K – 1461
2021
Q3 		$26K Buy
510
+5
+1% +$296 ﹤0.01% 1209
2021
Q2 		$34K Buy
505
+5
+1% +$349 ﹤0.01% 1077
2021
Q1 		$38K Buy
500
+50
+11% +$3.63K ﹤0.01% 861
2020
Q4 		$27K Buy
+450
New +$22.5K ﹤0.01% 809

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Penserra Capital Management's KRYS Position: Q4 2021 in Review

Penserra Capital Management sold out of Krystal Biotech (KRYS) in Q4 2021, closing a stake of 510 shares — an estimated $26K sold.

Penserra Capital Management first reported a position in KRYS in Q4 2020 and held it in 4 quarters. The position peaked at $38K in Q1 2021. 140 funds tracked by Wall St. Rank hold KRYS as of Q4 2021.

  • Penserra Capital Management reported no remaining Krystal Biotech position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 510 Krystal Biotech shares in Q4 2021, an estimated $26K.
  • Penserra Capital Management first reported a position in Krystal Biotech in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Krystal Biotech position peaked at $38K in Q1 2021.
  • 140 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.